Zentalis Pharmaceuticals, Inc.

NasdaqGM:ZNTL Stock Report

Market Cap: US$317.5m

Zentalis Pharmaceuticals Future Growth

Future criteria checks 2/6

Zentalis Pharmaceuticals is forecast to grow earnings and revenue by 20.9% and 61.6% per annum respectively. EPS is expected to grow by 27% per annum. Return on equity is forecast to be -91.7% in 3 years.

Key information

20.9%

Earnings growth rate

26.98%

EPS growth rate

Biotechs earnings growth25.1%
Revenue growth rate61.6%
Future return on equity-91.65%
Analyst coverage

Good

Last updated12 Jun 2026

Recent future growth updates

Analysis Article • May 09

Results: Zentalis Pharmaceuticals, Inc. Confounded Analyst Expectations With A Surprise Profit

Shareholders of Zentalis Pharmaceuticals, Inc. ( NASDAQ:ZNTL ) will be pleased this week, given that the stock price is...

Recent updates

Analysis Article • Jan 07

Zentalis Pharmaceuticals, Inc.'s (NASDAQ:ZNTL) Shares Bounce 28% But Its Business Still Trails The Industry

Zentalis Pharmaceuticals, Inc. ( NASDAQ:ZNTL ) shares have had a really impressive month, gaining 28% after a shaky...
Analysis Article • Jan 07

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Surges 28% Yet Its Low P/S Is No Reason For Excitement

Zentalis Pharmaceuticals, Inc. ( NASDAQ:ZNTL ) shareholders would be excited to see that the share price has had a...
Seeking Alpha • Dec 09

Zentalis Pharmaceuticals: Late Stage, Lots Of Cash, Crushed By The Market

Summary Zentalis has taken a serious beating in 2025 to date, as the market continues to value their pipeline as a liability rather than an asset. The company is in a bit of a holding pattern for now, but possible approval-worthy data are guided for the end of 2026. The market's disinterest in ZNTL creates a substantial, though risky, potential for upside as data gain more anticipation. Read the full article on Seeking Alpha
Analysis Article • Aug 27

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Surges 26% Yet Its Low P/S Is No Reason For Excitement

Zentalis Pharmaceuticals, Inc. ( NASDAQ:ZNTL ) shares have continued their recent momentum with a 26% gain in the last...
Analysis Article • Aug 16

Is Zentalis Pharmaceuticals (NASDAQ:ZNTL) In A Good Position To Deliver On Growth Plans?

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • Oct 03

We Think Zentalis Pharmaceuticals (NASDAQ:ZNTL) Needs To Drive Business Growth Carefully

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Analysis Article • Jun 19

Broker Revenue Forecasts For Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Are Surging Higher

Zentalis Pharmaceuticals, Inc. ( NASDAQ:ZNTL ) shareholders will have a reason to smile today, with the analysts making...
Analysis Article • Jun 13

We're Hopeful That Zentalis Pharmaceuticals (NASDAQ:ZNTL) Will Use Its Cash Wisely

We can readily understand why investors are attracted to unprofitable companies. For example, although...
Analysis Article • May 09

Results: Zentalis Pharmaceuticals, Inc. Confounded Analyst Expectations With A Surprise Profit

Shareholders of Zentalis Pharmaceuticals, Inc. ( NASDAQ:ZNTL ) will be pleased this week, given that the stock price is...
Seeking Alpha • Apr 12

Zentalis Pharmaceuticals: Data In 1st Half Of 2024 Could Get The Ball Rolling

Summary Zentalis Pharmaceuticals, Inc. expects final results from phase 1b study, using azenosertib + gemcitabine for the treatment of patients with osteosarcoma, in the 1st half of 2024. In a phase 1 study, using monotherapy azenosertib for 19 patients with platinum resistant or refractory ovarian cancer and uterine serous carcinoma patients, the ORR achieved was 37%. Initiation of a clinical trial using azenosertib for 1st-line maintenance platinum-sensitive ovarian cancer patients expected in 2025; Trial design to be revealed in the 2nd half of 2024. Zentalis received an upfront payment of $35 million and is eligible to earn up to $275 million payments in milestones plus royalties after out-licensing its ROR1 ADC to Immunome. Read the full article on Seeking Alpha
Analysis Article • Feb 29

We Think Zentalis Pharmaceuticals (NASDAQ:ZNTL) Can Afford To Drive Business Growth

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Seeking Alpha • Feb 05

Zentalis: Leading WEE1 Developer After AstraZeneca's Exit

Summary Zentalis Pharma has shelved its oral SERD and EGFR inhibitors due to competition and focused on ZN-c3, an inhibitor of WEE1. AZN left the WEE1 space last year, which is a cause for both worry and elation at ZNTL. ZNTL's pivotal data will only read out in late 2025 or early 2026, but some earlier data this year may help figure out ZNTL as an investment. Read the full article on Seeking Alpha
Analysis Article • Jan 09

Is Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Trading At A 45% Discount?

Key Insights Zentalis Pharmaceuticals' estimated fair value is US$29.89 based on 2 Stage Free Cash Flow to Equity...
Analysis Article • Oct 13

We're Not Very Worried About Zentalis Pharmaceuticals' (NASDAQ:ZNTL) Cash Burn Rate

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • Jun 30

We Think Zentalis Pharmaceuticals (NASDAQ:ZNTL) Can Afford To Drive Business Growth

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Analysis Article • Mar 17

We're Hopeful That Zentalis Pharmaceuticals (NASDAQ:ZNTL) Will Use Its Cash Wisely

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Analysis Article • Dec 01

We're Hopeful That Zentalis Pharmaceuticals (NASDAQ:ZNTL) Will Use Its Cash Wisely

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
Seeking Alpha • Sep 27

Zentalis Pharmaceuticals promotes co-founder Kevin Bunker to chief scientific officer

Clinical-stage biopharma Zentalis Pharmaceuticals (NASDAQ:ZNTL) on Tuesday said it had appointed its co-founder Kevin Bunker as chief scientific officer. "In this new role, (Bunker) will focus on leading Research and Development (R&D) in San Diego, advancing the preclinical pipeline and optimizing the Company’s Integrated Discovery Engine," the company said in a statement. Bunker had previously been chief operating officer at the company. ZNTL stock earlier closed +3.8% at $21.
Seeking Alpha • Sep 19

Zentalis Pharmaceuticals has a new chief medical officer

Zentalis Pharmaceuticals (NASDAQ:ZNTL) appoints with over two decades of medical and biopharmaceutical experienced Carrie Brownstein, MD, as Chief Medical Officer, effective October 3, 2022.
Analysis Article • Aug 17

Zentalis Pharmaceuticals (NASDAQ:ZNTL) Is In A Good Position To Deliver On Growth Plans

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Analysis Article • May 02

Here's Why We're Not Too Worried About Zentalis Pharmaceuticals' (NASDAQ:ZNTL) Cash Burn Situation

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
Analysis Article • Jan 12

We're Hopeful That Zentalis Pharmaceuticals (NASDAQ:ZNTL) Will Use Its Cash Wisely

We can readily understand why investors are attracted to unprofitable companies. For example, although...

Earnings and Revenue Growth Forecasts

NasdaqGM:ZNTL - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/202877-155-158-897
12/31/202721-154-166-869
12/31/2026N/A-150-157-628
3/31/2026N/A-124-126-126N/A
12/31/2025N/A-137-125-125N/A
9/30/202527-149-134-134N/A
6/30/202527-163-151-151N/A
3/31/202527-224-152-152N/A
12/31/202467-166-171-171N/A
9/30/202441-179-172-172N/A
6/30/202441-195-167-166N/A
3/31/202441-219-211-211N/A
12/31/2023N/A-292-208-208N/A
9/30/2023N/A-286-205-205N/A
6/30/2023N/A-285-201-199N/A
3/31/2023N/A-241-165-163N/A
12/31/2022N/A-237-166-164N/A
9/30/2022N/A-232-168-163N/A
6/30/2022N/A-182-169-164N/A
3/31/2022N/A-168-173-167N/A
12/31/2021N/A-159-160-154N/A
9/30/2021N/A-149-149-144N/A
6/30/2021N/A-179-133-132N/A
3/31/2021N/A-152-109-107N/A
12/31/2020N/A-118-88-87N/A
9/30/2020N/A-92-73-73N/A
6/30/2020N/A-70-62-62N/A
3/31/2020N/A-53-47-47N/A
12/31/2019N/A-46N/A-39N/A
12/31/20180-23N/A-24N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: ZNTL is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: ZNTL is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: ZNTL is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: ZNTL's revenue (61.6% per year) is forecast to grow faster than the US market (12.7% per year).

High Growth Revenue: ZNTL's revenue (61.6% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: ZNTL is forecast to be unprofitable in 3 years.

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/07/05 04:26
End of Day Share Price 2026/07/02 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Zentalis Pharmaceuticals, Inc. is covered by 15 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Michael SchmidtGuggenheim Securities, LLC
Andrew FeinH.C. Wainwright & Co.
Andres MaldonadoH.C. Wainwright & Co.